Aug. 14 at 7:49 PM
$VIVS
AI changed how we think. Robotics is changing how we build. Biotechnology could change how long — and how well — we live. 🧬
$VIVS is operating at the intersection of human-relevant 3D tissue models, organoids and AI-assisted drug development.
NAMKind™ is where the story gets especially interesting: using human 3D models to help predict drug toxicity and potentially reduce reliance on animal testing.
This is still an early-stage, high-risk company. The technology has to translate into customers, revenue and sustainable growth.
But if biotechnology becomes one of the next major technology cycles, companies building the infrastructure today are worth watching.
AI → Robotics → Biotechnology → Better human health & longevity.
$VIVS 🧬🔬
Not financial advice. High risk. Do your own research.
